First MelMax shipment sent to Europe
November 18, 2005

Rob Rueger, The Woundcare Company's Director of Manufacturing, completed and shipped the first batch of MelMax for subsequent sales and distribution by Dermagenics BV – Greystone's wholly owned European subsidiary.

MelMax cleared for sale in Europe
October 10, 2005

MelMax, The Woundcare Company's bacteriostatic wound dressing, has been cleared for sale in Europe as a class IIb medical device similar to DerMax. MelMax contains one-fourth the quantity of PHI used in DerMax, but also contains a bacteriostatic honey-based ointment. Honey-based wound dressings are becoming popular in Europe for treating infected wounds or wounds that are prone to becoming infected.

Televised interview with CEO Greg Pilant and Dr. Bob Moore
June 1, 2005

CEO Greg Pilant and researcher Dr. Bob Moore discussed The Woundcare Company's experimental hemostatic and hemorrhagic shock drugs on Memphis' WREG-TV Channel 3's Live @ Nine program. The interview is now available .

FDA clears Epi-Max for sale and use in U.S.
May 18, 2005

Epi-Max was cleared by the U.S. Food and Drug Administration for human use and sale in the United States. Epi-Max is a hybrid medical device with a drug component, which makes it significantly different from most other advanced wound care products. Click here for the full press release.